Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Suppression of tumorigenicity 13 (colon carcinoma) (Hsp70 interacting protein) pseudogene 14 (ST13P14) is a human pseudogene related to the ST13 (Hsp70 interacting protein) gene, which encodes a cochaperone protein involved in heat shock response and protein folding. ST13P14 itself does not encode a functional protein and is classified as a pseudogene, meaning it is generally not transcribed or translated into a functional product and has no established direct biological or therapeutic role[5][3][10]. While some pseudogenes can have regulatory roles, there is currently no evidence for transcriptional activity or functional impact of ST13P14 specifically[5][6][10]. Its parent gene, ST13, is recognized for tumor suppressor activity in colorectal carcinoma and participates in heat shock protein regulation, but these functions are not attributed to the pseudogene ST13P14[7][12]. Additional notes: - ST13P14 is not considered a therapeutic target, and there are no drugs or biomarkers associated with it. - The gene is catalogued in several gene product databases as a *pseudogene*, making it not a target for therapeutic intervention[5]. - The entry is fully consistent with standard nomenclature conventions, but as a pseudogene, its relevance is typically limited to genomic studies or regulatory RNA research, where no specific function for ST13P14 has yet been identified. Summary of evaluation: - This gene is not a functional receptor, enzyme, or known therapeutic target. - The target name and abbreviation are correct, but its consideration as a drug target or functional receptor is not supported. - It represents a typical pseudogene entry without evidence of coding or regulatory function in current literature[5][10][2].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Suppression of tumorigenicity 13 (colon carcinoma) (Hsp70 interacting protein) pseudogene 14 (ST13P14).